Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Asp Med. 2013;34:1217–56.

Article  CAS  Google Scholar 

Hernando Polo S, Moreno Muñoz D, Rosero Rodríguez AC, Silva Ruiz J, Rosero Rodríguez DI, Couñago F. Changing the history of prostate cancer with new targeted therapies. Biomedicines. 2021;9:332.

Article  Google Scholar 

Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev Anticancer Ther. 2020;20:715–26.

Article  CAS  PubMed  Google Scholar 

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. J Clin Oncol. 2018;36:991–9.

Article  CAS  PubMed  Google Scholar 

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;383:2345–57.

Article  CAS  PubMed  Google Scholar 

Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, et al. Non-BRCA DNA damage repair gene alterations and response to the parp inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 2022;18:425–36.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Published May 20, 2020. Access June 30, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.

US Food and Drug Administration. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. Published May 15, 2020. Accessed June 30, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091–102.

Article  PubMed  Google Scholar 

LYNPARZA (olaparib) tablets, for oral use. Prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 07/2019.

FoundationOne®CDx technical information. Cambridge, MA: Foundation Medicine Inc.; 2020.

FoundationONE Liquid CDx technical information. Cambridge, MA: Foundation Medicine Inc.; 2021.

BRACAnalysis CDx technical information. Salt Lake City, UT: Myriad Genetics Laboratories, Inc.; 2021.

Abida W, Bryce AH, Vogelzang NJ, Amato RJ, Percent I, Shapiro JD, et al. Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2018;29:793PD. Abstract

Article  Google Scholar 

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27:167–74.

Article  PubMed  PubMed Central  Google Scholar 

Leith A, Ribbands A, Last M, Gayle A, Payne S, McCrea C, et al. Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States. J Clin Oncol. 2021;39:49.

Article  Google Scholar 

Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17:2907–21.

Article  CAS  PubMed  Google Scholar 

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, et al. American Association for Cancer Research project genomics evidence neoplasia information exchange: From inception to first data release and beyond-lessons learned and member institutions’ perspectives. JCO Clin Cancer Inf. 2018;2:1–14.

Google Scholar 

Aggarwal S, Whipple S, Hsu H, Tu H, Carrigan G, Wang X, et al. Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB). Ann Oncol. 2020;31:1339P. Abstract

Article  Google Scholar 

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA. 2019;321:1391–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pugh TJ, Bell JL, Bruce JP, Doherty GJ, Galvin M, Green MF, et al. AACR Project GENIE: 100,000 cases and beyond. Cancer Discov. 2022;12:2044–57.

Article  PubMed  PubMed Central  Google Scholar 

LeVee A, Lin CY, Posadas E, Figlin R, Bhowmick NA, Di Vizio D, et al. Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: A review of current evidence and patient selection. Onco Targets Ther. 2021;14:4819–32.

Article  PubMed  PubMed Central  Google Scholar 

Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, structure, and scope. Hum Mutat. 2000;16:123–31.

Article  CAS  PubMed  Google Scholar 

Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980–5.

Article  CAS  PubMed  Google Scholar 

de Bono JS, Fizazi K, Saad F, Shore N, Sandhu SK, Mehra N, et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol. 2019;30:847PD. Abstract

Google Scholar 

Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J Urol. 2021;205:977–86.

Article  PubMed  Google Scholar 

Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, et al. Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res. 2022;28:318–26.

Article  CAS  PubMed  Google Scholar 

Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17:515–21.

Article  CAS  PubMed  Google Scholar 

Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, et al. Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol. 2020;4:442–65.

Article  PubMed  Google Scholar 

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50:645–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA, et al. Racial differences in genomic profiling of prostate cancer. N. Engl J Med. 2020;383:1083–5.

Article  PubMed  PubMed Central  Google Scholar 

Schumacher FR, Basourakos SP, Lewicki PJ, Vince R, Spratt DE, Barbieri CE, et al. Race and genetic alterations in prostate cancer. JCO Precis Oncol. 2021;5:1650–3.

Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021;81:433–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505.

Article  CAS  PubMed  Google Scholar 

Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. Future Oncol. 2022;18:937–51.

Article  CAS  PubMed  Google Scholar